1.28
-0.08 (-5.88%)
| Previous Close | 1.36 |
| Open | 1.34 |
| Volume | 9,795,310 |
| Avg. Volume (3M) | 5,148,241 |
| Market Cap | 1,078,552,320 |
| Price / Sales | 1.38 |
| Price / Book | 0.840 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -5.66% |
| Operating Margin (TTM) | -44.79% |
| Diluted EPS (TTM) | -0.060 |
| Quarterly Revenue Growth (YOY) | -13.70% |
| Total Debt/Equity (MRQ) | 37.58% |
| Current Ratio (MRQ) | 2.49 |
| Operating Cash Flow (TTM) | -182.48 M |
| Levered Free Cash Flow (TTM) | -107.74 M |
| Return on Assets (TTM) | -8.20% |
| Return on Equity (TTM) | -3.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Opko Health, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.13 |
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 46.81% |
| % Held by Institutions | 25.36% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 3.00 (HC Wainwright & Co., 134.38%) | Buy |
| Median | 2.63 (105.47%) | |
| Low | 2.25 (Barrington Research, 75.78%) | Buy |
| Average | 2.63 (105.47%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 1.44 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barrington Research | 01 May 2025 | 2.25 (75.78%) | Buy | 1.35 |
| 12 Mar 2025 | 2.25 (75.78%) | Buy | 1.78 | |
| HC Wainwright & Co. | 07 Apr 2025 | 3.00 (134.38%) | Buy | 1.53 |
| 19 Mar 2025 | 3.00 (134.38%) | Buy | 1.86 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |